atropine has been researched along with cifenline in 6 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (cifenline) | Trials (cifenline) | Recent Studies (post-2010) (cifenline) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 303 | 49 | 33 |
| Protein | Taxonomy | atropine (IC50) | cifenline (IC50) |
|---|---|---|---|
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | 7.8 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.8 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | 7.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Boucher, M; Cazes, M; Chassaing, C; Cloarec, A; Duchêne-Marullaz, P; Martinet, M; Provost, D | 1 |
6 other study(ies) available for atropine and cifenline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of anticholinergic effects of cibenzoline, disopyramide, and atropine.
Topics: Animals; Atropine; Brain; Cerebral Cortex; Disopyramide; Dogs; Electric Stimulation; Female; Heart; Heart Rate; Imidazoles; In Vitro Techniques; Infusions, Intravenous; Injections, Intravenous; Male; Membranes; Myocardium; Parasympatholytics; Rats; Rats, Inbred Strains; Vagus Nerve | 1990 |